Mountain View, CA – January 5, 2015 – Amunix Operating Inc. (Amunix), a leader in the field of protein half-life extension, today announced a research and development partnership with Naia Limited (Naia), an international drug development company that employs an innovative global strategy to clinically advance drug candidates. Amunix and Naia signed two exclusive worldwide licenses to further develop two Amunix receptor agonist product candidates: GLP-1-XTEN, a glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes and GLP-2-XTEN, a glucagon-like peptide-2 receptor agonist for the treatment of short bowel syndrome.
Under the terms of each license agreement, Naia will be responsible for all preclinical and clinical activities of the product resulting from the collaboration. Upon achievement of certain development, regulatory, commercial and sales-based milestones, Amunix will be eligible to receive milestones totaling up to $70 million for each project, as well as tiered royalties on worldwide annual net sales for the licensed products upon commercialization.
“We are delighted to enter into this strategic partnership and we look forward to our collaboration with Naia, a new company founded and led by an experienced management team in the field of drug development,” said Volker.